Raymond Dingledine

No ORCID on file · 3 papers in corpus
lab-animal 2023
Preclinical development of an EP2 antagonist for post-seizure cognitive deficits
Neuropharmacology ·doi:10.1016/j.neuropharm.2022.109356

Cognitive comorbidities can substantially reduce quality of life in people with epilepsy. Inflammation is a component of all chronic diseases including epilepsy, as well as acute events like status epilepticus (SE). Neuroinflammation is the…

lab-animal 2022
Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie ·doi:10.1016/j.biopha.2022.112646

The EP2 receptor has emerged as a therapeutic target with exacerbating role in disease pathology for a variety of peripheral and central nervous system disorders. We and others have recently demonstrated beneficial effects of EP2 antagonist…

lab-animal 2022
Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties
ACS pharmacology & translational science ·doi:10.1021/acsptsci.1c00255

EP2, a G-protein-coupled prostaglandin-E2 receptor, has emerged as a seminal biological target for drug discovery. EP2 receptor activation is typically proinflammatory; therefore, the development of EP2 antagonists to mitigate the severity …